(DOCS) Doximity - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US26622P1075
Stock: Platform, Network, Collaboration, Telehealth, Recruitment
Total Rating 35
Risk 92
Buy Signal -0.11
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 109% |
| Relative Tail Risk | -27.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.95 |
| Alpha | -69.44 |
| Character TTM | |
|---|---|
| Beta | 1.129 |
| Beta Downside | 1.413 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.65% |
| CAGR/Max DD | -0.07 |
Description: DOCS Doximity January 03, 2026
Doximity, Inc. (NYSE: DOCS) runs a U.S.-focused digital network for physicians, nurse practitioners, physician assistants, medical students, pharma firms, and health systems, offering tools for peer collaboration, news aggregation, career management, on-call scheduling, documentation, and virtual patient visits.
Founded in 2010 (originally 3MD Communications) and headquartered in San Francisco, the company sits in the Health Care Technology sub-industry and trades as common stock.
Key recent metrics: FY 2023 revenue topped $460 million, up ~30 % YoY, driven by a 20 % increase in advertising spend and a 15 % rise in subscription-based services; the platform now reaches roughly 84 % of U.S. physicians, giving it a highly defensible network effect.
Sector drivers include accelerating adoption of telehealth post-COVID-19, ongoing physician shortages that push clinicians toward efficiency-enhancing software, and rising health-system budgets for digital infrastructure, all of which support Doximity’s growth outlook.
For a deeper dive into Doximity’s valuation and risk profile, check the ValueRay analysis page.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 239.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.27 > 0.02 and ΔFCF/TA 7.33 > 1.0 |
| NWC/Revenue: 132.3% < 20% (prev 163.0%; Δ -30.74% < -1%) |
| CFO/TA 0.27 > 3% & CFO 315.4m > Net Income 239.4m |
| Net Debt (-54.1m) to EBITDA (268.5m): -0.20 < 3 |
| Current Ratio: 6.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (199.2m) vs 12m ago -1.49% < -2% |
| Gross Margin: 89.75% > 18% (prev 0.90%; Δ 8885 % > 0.5%) |
| Asset Turnover: 54.76% > 50% (prev 46.94%; Δ 7.83% > 0%) |
| Interest Coverage Ratio: -2.05 > 6 (EBITDA TTM 268.5m / Interest Expense TTM -90.5m) |
Altman Z'' 6.05
| A: 0.73 (Total Current Assets 993.5m - Total Current Liabilities 149.8m) / Total Assets 1.16b |
| B: 0.02 (Retained Earnings 21.0m / Total Assets 1.16b) |
| C: 0.16 (EBIT TTM 185.8m / Avg Total Assets 1.16b) |
| D: 0.13 (Book Value of Equity 22.6m / Total Liabilities 177.7m) |
| Altman-Z'' Score: 6.05 = AAA |
Beneish M -2.97
| DSRI: 0.98 (Receivables 156.6m/137.5m, Revenue 637.8m/550.2m) |
| GMI: 1.00 (GM 89.75% / 90.19%) |
| AQI: 1.03 (AQ_t 0.12 / AQ_t-1 0.12) |
| SGI: 1.16 (Revenue 637.8m / 550.2m) |
| TATA: -0.07 (NI 239.4m - CFO 315.4m) / TA 1.16b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of DOCS shares?
As of February 09, 2026, the stock is trading at USD 27.73 with a total of 22,179,473 shares traded.
Over the past week, the price has changed by -25.64%, over one month by -36.60%, over three months by -47.22% and over the past year by -66.65%.
Over the past week, the price has changed by -25.64%, over one month by -36.60%, over three months by -47.22% and over the past year by -66.65%.
Is DOCS a buy, sell or hold?
Doximity has received a consensus analysts rating of 3.68.
Therefor, it is recommend to hold DOCS.
- StrongBuy: 5
- Buy: 3
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DOCS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 46.9 | 69.1% |
| Analysts Target Price | 46.9 | 69.1% |
| ValueRay Target Price | 26.4 | -4.7% |
DOCS Fundamental Data Overview February 08, 2026
P/E Trailing = 23.3025
P/E Forward = 16.129
P/S = 8.1858
P/B = 5.2303
P/EG = 0.701
Revenue TTM = 637.8m USD
EBIT TTM = 185.8m USD
EBITDA TTM = 268.5m USD
Long Term Debt = 10.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.08m USD (from shortTermDebt, last quarter)
Debt = 10.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -54.1m USD (from netDebt column, last quarter)
Enterprise Value = 4.50b USD (5.22b + Debt 10.7m - CCE 735.1m)
Interest Coverage Ratio = -2.05 (Ebit TTM 185.8m / Interest Expense TTM -90.5m)
EV/FCF = 14.32x (Enterprise Value 4.50b / FCF TTM 313.9m)
FCF Yield = 6.98% (FCF TTM 313.9m / Enterprise Value 4.50b)
FCF Margin = 49.22% (FCF TTM 313.9m / Revenue TTM 637.8m)
Net Margin = 37.54% (Net Income TTM 239.4m / Revenue TTM 637.8m)
Gross Margin = 89.75% ((Revenue TTM 637.8m - Cost of Revenue TTM 65.4m) / Revenue TTM)
Gross Margin QoQ = 89.89% (prev 90.25%)
Tobins Q-Ratio = 3.89 (Enterprise Value 4.50b / Total Assets 1.16b)
Interest Expense / Debt = 36.24% (Interest Expense 3.88m / Debt 10.7m)
Taxrate = 23.81% (19.2m / 80.8m)
NOPAT = 141.5m (EBIT 185.8m * (1 - 23.81%))
Current Ratio = 6.63 (Total Current Assets 993.5m / Total Current Liabilities 149.8m)
Debt / Equity = 0.01 (Debt 10.7m / totalStockholderEquity, last quarter 979.3m)
Debt / EBITDA = -0.20 (Net Debt -54.1m / EBITDA 268.5m)
Debt / FCF = -0.17 (Net Debt -54.1m / FCF TTM 313.9m)
Total Stockholder Equity = 1.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.56% (Net Income 239.4m / Total Assets 1.16b)
RoE = 22.89% (Net Income TTM 239.4m / Total Stockholder Equity 1.05b)
RoCE = 17.58% (EBIT 185.8m / Capital Employed (Equity 1.05b + L.T.Debt 10.7m))
RoIC = 13.53% (NOPAT 141.5m / Invested Capital 1.05b)
WACC = 10.12% (E(5.22b)/V(5.23b) * Re(10.08%) + D(10.7m)/V(5.23b) * Rd(36.24%) * (1-Tc(0.24)))
Discount Rate = 10.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.31%
[DCF Debug] Terminal Value 74.70% ; FCFF base≈281.2m ; Y1≈346.8m ; Y5≈590.7m
Fair Price DCF = 52.46 (EV 6.96b - Net Debt -54.1m = Equity 7.02b / Shares 133.8m; r=10.12% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 92.50 | EPS CAGR: 23.26% | SUE: 0.35 | # QB: 0
Revenue Correlation: 93.97 | Revenue CAGR: 19.91% | SUE: 0.72 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.35 | Chg30d=-0.024 | Revisions Net=+1 | Analysts=13
EPS next Year (2027-03-31): EPS=1.66 | Chg30d=-0.063 | Revisions Net=+1 | Growth EPS=+7.0% | Growth Revenue=+9.5%
P/E Forward = 16.129
P/S = 8.1858
P/B = 5.2303
P/EG = 0.701
Revenue TTM = 637.8m USD
EBIT TTM = 185.8m USD
EBITDA TTM = 268.5m USD
Long Term Debt = 10.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.08m USD (from shortTermDebt, last quarter)
Debt = 10.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -54.1m USD (from netDebt column, last quarter)
Enterprise Value = 4.50b USD (5.22b + Debt 10.7m - CCE 735.1m)
Interest Coverage Ratio = -2.05 (Ebit TTM 185.8m / Interest Expense TTM -90.5m)
EV/FCF = 14.32x (Enterprise Value 4.50b / FCF TTM 313.9m)
FCF Yield = 6.98% (FCF TTM 313.9m / Enterprise Value 4.50b)
FCF Margin = 49.22% (FCF TTM 313.9m / Revenue TTM 637.8m)
Net Margin = 37.54% (Net Income TTM 239.4m / Revenue TTM 637.8m)
Gross Margin = 89.75% ((Revenue TTM 637.8m - Cost of Revenue TTM 65.4m) / Revenue TTM)
Gross Margin QoQ = 89.89% (prev 90.25%)
Tobins Q-Ratio = 3.89 (Enterprise Value 4.50b / Total Assets 1.16b)
Interest Expense / Debt = 36.24% (Interest Expense 3.88m / Debt 10.7m)
Taxrate = 23.81% (19.2m / 80.8m)
NOPAT = 141.5m (EBIT 185.8m * (1 - 23.81%))
Current Ratio = 6.63 (Total Current Assets 993.5m / Total Current Liabilities 149.8m)
Debt / Equity = 0.01 (Debt 10.7m / totalStockholderEquity, last quarter 979.3m)
Debt / EBITDA = -0.20 (Net Debt -54.1m / EBITDA 268.5m)
Debt / FCF = -0.17 (Net Debt -54.1m / FCF TTM 313.9m)
Total Stockholder Equity = 1.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.56% (Net Income 239.4m / Total Assets 1.16b)
RoE = 22.89% (Net Income TTM 239.4m / Total Stockholder Equity 1.05b)
RoCE = 17.58% (EBIT 185.8m / Capital Employed (Equity 1.05b + L.T.Debt 10.7m))
RoIC = 13.53% (NOPAT 141.5m / Invested Capital 1.05b)
WACC = 10.12% (E(5.22b)/V(5.23b) * Re(10.08%) + D(10.7m)/V(5.23b) * Rd(36.24%) * (1-Tc(0.24)))
Discount Rate = 10.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.31%
[DCF Debug] Terminal Value 74.70% ; FCFF base≈281.2m ; Y1≈346.8m ; Y5≈590.7m
Fair Price DCF = 52.46 (EV 6.96b - Net Debt -54.1m = Equity 7.02b / Shares 133.8m; r=10.12% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 92.50 | EPS CAGR: 23.26% | SUE: 0.35 | # QB: 0
Revenue Correlation: 93.97 | Revenue CAGR: 19.91% | SUE: 0.72 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.35 | Chg30d=-0.024 | Revisions Net=+1 | Analysts=13
EPS next Year (2027-03-31): EPS=1.66 | Chg30d=-0.063 | Revisions Net=+1 | Growth EPS=+7.0% | Growth Revenue=+9.5%